Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews findings from a phase II trial of pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation (Abstract 89).
Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL) (Abstract 1).
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516).
Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicin–based therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441).
Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the University of Oxford, discusses initial results of the phase II/III UK-based RADAR trial. The study evaluated isatuximab, bortezomib, lenalidomide, dexamethasone, and cyclophosphamide induction, followed by single autologous stem cell transplant, consolidation with isatuximab plus bortezomib, lenalidomide, and dexamethasone, and isatuximab plus lenalidomide maintenance, in patients with double-hit multiple myeloma (Abstract 98).
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or BCL-2 inhibitors (Abstract 87).
